To expand access to innovative medical technologies, the World Health Organization (WHO) has released a list of devices it believes could help meet broad global health needs and Masimo’s portable, palm-sized Pronto-7, is represented as “2.5 transcutaneous anaemia monitoring system.” The list consists of 15 medical devices that represent accessible and affordable healthcare solutions for use in low- and middle-income countries. This new device is now making its way into hospitals and physician offices near you…to see video of it in action, 2.5 Transcutaneous anaemia monitoring system
According to the WHO: “The intended purpose of the transcutaneous anaemia monitoring system is to screen populations for insufficient levels of haemoglobin in the blood and to carry out diagnosis of severe anaemia.” Anaemia affects 1.6 billion people worldwide, causes one million deaths a year, is a top-ten risk factor contributing to the global burden of disease, and results in lost cognitive function and productivity that is estimated to cost $50 billion annually in gross domestic product (GDP) losses worldwide.
Hemoglobin is one of the most commonly ordered tests in both hospital and non-hospital settings because it is critical to assessing anemia and blood loss. However, traditional lab testing requires a painful needle stick for the patient, time-consuming blood draws for the clinician, and typically provides delayed results. The palm-sized Pronto-7-with dimensions of just 5.1″ x 2.8″ x 1″ and weight of 10.5 ounces-represents a breakthrough solution for measuring hemoglobin in less than one minute. It puts the power of noninvasive hemoglobin spot-check testing into any clinician’s hands in almost any environment-without the needles, time-consuming laboratory analysis, risk of blood contamination, hazardous medical waste, and patient discomfort associated with traditional blood tests.
According to Aryeh Shander, M.D., President-Elect of the Society for the Advancement of Blood Management (SABM) and the Executive Medical Director for The Institute for Patient Blood Management & Bloodless Medicine and Surgery at Englewood Hospital and Medical Center in Englewood, New Jersey, “Noninvasive hemoglobin testing at the point-of-care offers a giant leap forward in our ability to tackle the global burden of anaemia. Although it is a common blood disorder, it is grossly under-tested and under-diagnosed. And, if left untreated, anaemia has a variety of serious health consequences and complications. The beauty of immediate, noninvasive hemoglobin testing is that it will allow more patients to be assessed, so their physician can determine additional test options and initiate potentially lifesaving treatment.”